Instructions for Atorvastatin tablets
English product name
Atorvastatin Medisorb
Release Form
tab. film sheath 10 mg: 14, 21, 28, 30, 40, 50, 60 or 100 pcs.
tab. film sheath 20 mg: 14, 21, 28, 30, 40, 50, 60 or 100 pcs.
tab. film sheath 40 mg: 14, 21, 28, 30, 40, 50, 60 or 100 pcs.
Description
The tablets are coated with a white film shell and are round, double-convex, with a white cross-section core.
1 tab.
atorvastatin calcium 10.84 mg
which corresponds to the content of atorvastatin 10 mg
Auxiliary substances: lactose monohydrate - 94.16 mg, potato starch - 9.3 mg, calcium carbonate - 6.5 mg, hyprolose (hydroxypropyl cellulose) - 2.7 mg, sodium croscarmellose - 2.6 mg, talc - 2.6 mg, calcium stearate - 1.3 mg.
Film sheath composition: hypromellose (hydroxypropyl methylcellulose) - 2.56 mg, macrogol-6000 (polyethylene glycol high molecular weight) - 0.54 mg, talc - 0.72 mg, titanium dioxide - 0.18 mg
ATC codes
C10AA05 Atorvastatin
Clinical-pharmacological groups / Group affiliation
Hypolipidemic drug
Active substance
atorvastatin
Pharmaco-therapeutic group Atorvastatin
Hypolipidemic agent - reductase inhibitor GMG-CoA
Pharmacological effect Atorvastatin
Hypolipidemic agent from the group of statins. By the principle of competitive antagonism, the statin molecule binds to the part of the coenzyme A receptor where GMG-CoA reductase is attached. Another part of the statin molecule inhibits the process of converting hydroxymethylglutarate into mevalonate, an intermediate product in the synthesis of the cholesterol molecule. Inhibition of HMG-CoA reductase activity results in a series of sequential reactions that reduce intracellular cholesterol and compensatory enhancement of LDL receptor activity and, correspondingly, acceleration of LDL cholesterol catabolism (Xc).
Testimony Atorvastatin
- Primary hypercholesterolaemia (heterozygous familial and nonfamilial hypercholesterolaemia (type IIa of Fredrikson's
- classification);
- combination (mixed) hyperlipidemia (types IIa and IIb of Fredrikson's classification);
- dysbetalipoproteinemia (type III of Fredrikson's classification) (as a supplement to the diet);
- family endogenous hypertriglyceridemia (type IV of Fredrikson's classification),
- diete-resistant;
- homozygous familial hypercholesterinemia with insufficient efficacy Dieting and other non-pharmacological treatments.
- Primary prevention of cardiovascular complications in patients without clinical signs of IBS, but with several risk factors of
- its development - age over 55 years,
- nicotine dependence,
- arterial hypertension,
- diabetes mellitus,
- low concentrations of Hs-HDL in blood plasma, genetic predisposition,
- including on the background of dylipidemia.
- Primary prevention of cardiovascular complications in patients without clinical signs of IBS,
- but with several risk factors of its development - age over 55 years,
- nicotine dependence,
- arterial hypertension,
- diabetes mellitus, low concentrations of Hs-HDL in blood plasma, genetic predisposition,
- including on the background of dylipidemia.
- Secondary prevention of cardiovascular complications in patients with IBS in order to reduce total mortality,
- myocardial infarction,
- stroke,
- repeated angina hospitalization and the need for revascularization.
Method of use, course and dosage Atorvastatin
The treatment is carried out against the background of the standard diet for patients with hypercholesterolemia. The dose is set individually, depending on the initial cholesterol level. Taken inside. The initial dose is usually ten mg once a day. The effect lasts two weeks and the maximum effect lasts four weeks. If necessary, the dose can be gradually increased at intervals of four weeks or more. The maximum daily dose is eighty mg.
Use in children
In children, atorvastatin has limited experience in doses up to 80 mg/day.
- Nosology (ICD codes)
- E78.0
- Pure hypercholesterolemia
- E78.1
- Pure hyperglyceridemia
- E78.2
- Mixed hyperlipidemia
